Introduction {#ss1}
============

Dipeptidyl peptidase‐4 (DPP‐4) inhibitors, a new therapeutic class of agents, target the incretin axis for the treatment of type 2 diabetes[^1,2^](#b1 b2){ref-type="ref"}. Incretins are released by the intestine at basal levels throughout the day, and secretion significantly increases in response to a meal; however, incretins are rapidly degraded by the peptidase enzyme, DPP‐4. DPP‐4 inhibitors stabilize the intact forms of the incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP)[^3,4^](#b3 b4){ref-type="ref"}. Intact GLP‐1 and GIP play an important role in glycemic homeostasis[^5^](#b5){ref-type="ref"} through multiple physiological actions including stimulation of insulin secretion (GLP‐1 and GIP) and suppression of glucagon secretion (GLP‐1), both in a glucose‐dependent fashion.

Sitagliptin is a highly selective DPP‐4 inhibitor dosed once daily. Several large, randomized, placebo‐controlled trials have shown that sitagliptin in monotherapy or in combination with other oral antihyperglycemic agents (AHA)[^6--12^](#b6 b7 b8 b9 b10 b11 b12){ref-type="ref"} provides significant improvements in key glycemic parameters, including fasting and postprandial glucose and HbA1c, relative to placebo, and is generally well tolerated.

Peroxisome proliferator‐activated receptor‐γ (PPARγ) agonists act primarily by decreasing insulin resistance in the liver and peripheral tissues. Pioglitazone is a PPARγ agonist widely used to treat type 2 diabetes[^13^](#b13){ref-type="ref"} that has been shown to be effective as an AHA in large, randomized, placebo‐controlled trials[^14,15^](#b14 b15){ref-type="ref"}.

A previous study, carried out outside of Japan, showed that the addition of sitagliptin to ongoing pioglitazone therapy in patients with type 2 diabetes improves glycemic control compared with placebo and is well tolerated[^12^](#b12){ref-type="ref"}. Because the pathological mechanisms underlying type 2 diabetes might be different in Japanese patients compared with patients from other ethnic and genetic backgrounds[^16--19^](#b16 b17 b18 b19){ref-type="ref"}, the present study assessed the efficacy and safety of sitagliptin as an add‐on to pioglitazone therapy in Japanese patients with type 2 diabetes.

Materials and Methods {#ss2}
=====================

Patients {#ss3}
--------

Eligible patients were men and women ≥20 years of age with type 2 diabetes being treated with pioglitazone (15--45 mg/day) as monotherapy or in combination with other oral AHA. Major exclusion criteria included: history of type 1 diabetes, recent treatment with insulin, the presence of progressive diabetes complications, unstable cardiovascular disease or uncontrolled severe hypertension, increased serum creatinine (\>132.6 μmol/L in men or \>114.9 μmol/L in women), increased alanine aminotransferase or aspartate aminotransferase \>2‐fold the upper limit of normal, hemoglobin \<110 g/L in men or \<100 g/L in women, or body mass index (BMI) \<18 or \>40 kg/m^2^.

Study Design and Procedures {#ss4}
---------------------------

This was a multicenter, randomized clinical trial carried out at 32 sites in Japan. The study included an initial 12‐week, placebo‐controlled, double‐blind treatment period that assessed the primary efficacy hypothesis, followed by a 40‐week, open‐label treatment period during which all patients received sitagliptin.

At screening, patients on a stable regimen of diet/exercise for at least 6 weeks and a stable dose of pioglitazone for at least 14 weeks (with the final 8 or more weeks as monotherapy only) and who met all eligibility criteria, including having a hemoglobin A1c (HbA1c) value ≥6.9% and \<10.4% (HbA1c \[%\] value is calculated by the formula HbA1c \[%\] = HbA1c \[Japan Diabetes Society (JDS)\] \[%\] + 0.4%, considering the relational expression of HbA1c \[JDS\] \[%\] measured by the previous Japanese standard substance and measurement methods and HbA1c \[National Glycohemoglobin Standardization Program\])[^20^](#b20){ref-type="ref"} could directly enter a 2‐week, single‐blind, placebo run‐in period. Otherwise, patients on combination therapy with pioglitazone and other oral AHA who met all eligibility criteria, with HbA1c values ≥6.4% and ≤9.4%, entered a 6‐week wash‐off period of non‐pioglitazone AHA after which they could enter the placebo run‐in period. This design ensured that all patients received at least 8 weeks of diet/exercise therapy and at least 16 weeks of pioglitazone therapy at a stable dose (with the final 8 or more weeks as monotherapy only) before randomization. All patients were instructed to follow a stable program of diet and exercise for the duration of the study.

Patients were eligible for randomization if they had a HbA1c ≥ 6.9% and \<10.4%, and a fasting plasma glucose (FPG) ≤ 15.0 mmol/L just before initiating the placebo run‐in and ≥75% treatment compliance (based on pill counts) during the placebo run‐in. Eligible patients were randomized (1:1) to either sitagliptin 50 mg/day or matching placebo for 12 weeks in a double‐blind fashion, using a computer‐generated allocation schedule.

On completion of the double‐blind period, patients entered a 40‐week, open‐label treatment period. Patients who received sitagliptin during the double‐blind period continued to do so in the open‐label period (S/S group). Patients who received the placebo in the double‐blind period were started on sitagliptin 50 mg/day at entry to the open‐label period (P/S group). Regardless of group, patients had their sitagliptin dose increased to 100 mg/day at the next study visit if FPG was ≥7.8 mmol/L on or after week 16, or if HbA1c was ≥7.4% on or after week 24; after week 40, the sitagliptin dose remained stable until study end. Investigators could decrease the sitagliptin dose to 50 mg/day if treatment with 100 mg/day was not considered to be well tolerated. Patients were required to be discontinued from the study if FPG was consistently (on two consecutive determinations) \>15.0 mmol/L at any time during the study or if HbA1c was consistently \>8.4% at or after week 40.

Meal tolerance tests were carried out at weeks 0, 12 and 52, beginning 30 min after administration of the study drug (at week 0 patients received a dose of the matching placebo). The test meal contained approximately 500 kcal (60% carbohydrate, 15% protein and 25% fat), and was to be consumed within 15 min. Blood samples were drawn before beginning the test meal and 0.5, 1.0 and 2.0 h after beginning the meal.

The present study was designed and carried out in accordance with the guidelines on good clinical practice and ethical principles stated in the Declaration of Helsinki. The study protocol was approved by the institutional review board at each study site. All patients provided written informed consent.

Study End‐points {#ss5}
----------------

The primary efficacy end‐point was change from baseline in HbA1c at week 12. Secondary end‐points were change from baseline in FPG and 2‐h post‐meal glucose (2‐h PMG) at week 12. In the open‐label period, HbA1c, FPG and 2‐h PMG were assessed as exploratory end‐points. Additional exploratory end‐points included fasting 1,5‐anhydroglucitol (1,5‐AG), insulin, homeostasis model assessment of β‐cell function (HOMA‐β), homeostasis model assessment of insulin resistance (HOMA‐IR)[^21^](#b21){ref-type="ref"}, 2‐h post‐meal insulin, post‐meal glucose area under the concentration‐versus‐time curve (AUC), insulin AUC, C‐peptide AUC and insulinogenic index[^22^](#b22){ref-type="ref"} assessed at both weeks 12 and 52. The proportions of patients with HbA1c values meeting the therapeutic goals of \<7.4% and \<6.9%, (corresponding to 7.0 and 6.5% in HbA1c \[JDS\], respectively) were also assessed at weeks 12 and 52.

Adverse experiences (AE) were monitored throughout the study up to 2 weeks post‐treatment, and investigators rated their intensity and relationship to the study drug. Hypoglycemia and selected gastrointestinal AE (nausea, vomiting and diarrhea) were predefined for additional analyses. Hypoglycemia was diagnosed by the investigators based on their assessment of patients' reports. Patients were instructed to notify the investigator immediately if they had symptoms consistent with hypoglycemia (e.g. sweating, anxiety, palpitations, blurred vision, loss of consciousness) that required assistance or if they had self‐monitoring blood glucose values \<3.3 or \>15.0 mmol/L. Safety and tolerability were also assessed during the study by physical examination, monitoring of vital signs, and safety laboratory tests, including hematology, serum chemistry and urinalysis.

Laboratory assays were carried out at one central laboratory (Mitsubishi Chemical Medience Corporation, Tokyo, Japan).

Statistical Methods {#ss6}
-------------------

### Efficacy {#ss7}

The efficacy analysis was carried out on the full analysis set (FAS) population composed of all randomized patients who had taken at least one dose of the study drug and had both the baseline and at least one post‐randomization measurement. An analysis of covariance ([ancova]{.smallcaps}) model was used to compare treatment groups for continuous efficacy parameters, focusing on change from baseline at week 12, with treatment group, baseline values and prior oral AHA status other than pioglitazone (on or not on) as covariates. Missing values of HbA1c and FPG were imputed by the last‐observation‐carried‐forward (LOCF) method; missing values for 2‐h PMG were not imputed. The between‐group difference in least squares (LS) mean and 95% confidence intervals (CI) were estimated with an alpha level of \<0.05 (two‐sided) considered statistically significant. The proportions of patients with HbA1c values meeting the predefined HbA1c goals were analyzed using a logistic regression model that included treatment group, prior oral AHA status and baseline HbA1c as covariates.

To assess the consistency of the HbA1c‐lowering effect of sitagliptin across subgroups, between‐group differences in LS mean changes from baseline and 95% CI were estimated using the [ancova]{.smallcaps} model described earlier for each subgroup defined by prior oral AHA status other than pioglitazone (on or not on), baseline HbA1c (≤8.4 or \>8.4%), age (\<65 or ≥65 years), sex, BMI (\<25 or ≥25 kg/m^2^), duration of type 2 diabetes (\<median or ≥median), fasting insulin (\<median or ≥median), HOMA‐IR (\<median or ≥median) and HOMA‐β (\<median or ≥median). For these analyses, the [ancova]{.smallcaps} model did not include the covariates of baseline HbA1c value and prior oral AHA status for each subgroup variable.

For longer‐term assessment of efficacy, summary statistics for efficacy end‐points were provided, by treatment group (P/S or S/S), at each time‐point in which the end‐point was measured up to week 52; missing values were not imputed. At week 52, the within‐group mean change from baseline for all efficacy end‐points was assessed using a paired *t‐*test.

The effect of uptitrating the sitagliptin dose to 100 mg/day was assessed (*post‐hoc*). Among patients whose sitagliptin dose was increased and whose HbA1c value at the time of uptitration was ≥7.4%, the proportion of patients with HbA1c values \<7.4% 12 weeks after uptitration was tabulated. Additionally, for patients whose sitagliptin dose was increased and who completed the study, the proportion of patients with HbA1c values \<7.4% at week 52 was also assessed. For these analyses, missing values were not imputed.

### Safety {#ss8}

Safety and tolerability analyses were carried out on the all‐patients‐as‐treated (APaT) population, which included randomized patients who received at least one dose of the double‐blind study drug. In the double‐blind period, between‐group comparisons using Fisher's exact test were carried out for incidences of overall (one or more) AE, drug‐related clinical AE, hypoglycemia and prespecified gastrointestinal AE. The analysis of change from baseline in bodyweight was carried out (*post‐hoc*) using an [ancova]{.smallcaps} model similar to that used for the efficacy end‐points.

For longer‐term safety assessment, the patient population included all patients who received at least one dose of sitagliptin after week 12. The incidences of overall AE, drug‐related AE, hypoglycemia and selected gastrointestinal AE were summarized. Within‐group mean change from baseline in bodyweight was assessed using a paired *t*‐test at week 52.

Results {#ss9}
=======

Of the 165 patients screened, 134 were randomized to treatment (66 to sitagliptin and 68 to placebo; [Figure 1](#f1){ref-type="fig"}). Demographic, anthropometric and disease characteristics were generally similar in both treatment groups, except for a greater proportion of females in the sitagliptin group (42%) compared with the placebo group (28%; Table S1). Patients had a baseline mean HbA1c of 8.1%, the average duration of known diabetes was 7.9 years and the mean BMI was 26.4 kg/m^2^.

![ Patient disposition. Patients in the P/S group received placebo during the double‐blind period and sitagliptin 50 or 100 mg in the open‐label period. Patients in the S/S group received sitagliptin in both periods. \*One patient who discontinued for lack of efficacy at week 50 was included in the efficacy analyses at week 52, thus increasing the group size to 50 patients.](jdi-2-381-g1){#f1}

A total of 130 patients completed the double‐blind period and entered the open‐label period; of those, 108 patients subsequently completed the open‐label period ([Figure 1](#f1){ref-type="fig"}). All randomized patients were included in the FAS and in the APaT populations for analysis.

Efficacy {#ss10}
--------

### Double‐blind period (weeks 0 through 12) {#ss11}

In Japanese patients receiving pioglitazone therapy, the addition of sitagliptin resulted in a significant (*P *\< 0.001) reduction from baseline in HbA1c compared with the placebo at week 12 ([Table 1](#t1){ref-type="table-wrap"}, [Figure 2](#f2){ref-type="fig"}). Additionally, a significantly greater proportion of patients in the sitagliptin group relative to the placebo group had HbA1c values \<7.4% (43% vs 12%, respectively; *P *\< 0.001), and \<6.9% (17% vs 3%, respectively; *P *\< 0.01). The effect of sitagliptin was generally consistent in all patient subgroups examined.

######  Results for fasting and post‐meal glycemic end‐points at week 12 (double‐blind period)

                                       *n*   Week 0 mean (SD)   Week 12 mean (SD)   Change from week 0 to 12 (LS mean \[95% CI\])   Between‐group difference (LS mean \[95% CI\])
  ------------------------------------ ----- ------------------ ------------------- ----------------------------------------------- -----------------------------------------------
  HbA1c^†^ (%)                                                                                                                      
   Placebo                             68    8.0 (0.8)          8.4 (1.2)           0.4 (0.3 to 0.5)\*\*\*                          −0.8 (−1.0 to −0.6)\*\*\*
   Sitagliptin                         66    8.1 (0.9)          7.7 (1.0)           −0.4 (−0.6 to −0.3)\*\*\*                       
  Fasting plasma glucose^†^ (mmol/L)                                                                                                
   Placebo                             68    8.54 (1.9)         8.6 (2.1)           0.2 (0.0 to 0.5)                                −0.9 (−1.3 to −0.6)\*\*\*
   Sitagliptin                         66    8.2 (1.8)          7.5 (1.5)           −0.7 (−0.9 to −0.4)\*\*\*                       
  1,5‐anhydroglucitol^†^ (μg/mL)                                                                                                    
   Placebo                             68    6.5 (5.3)          6.2 (5.5)           −0.3 (−0.8 to 0.3)                              3.7 (2.8 to 4.5)\*\*\*
   Sitagliptin                         66    6.0 (4.2)          9.4 (5.9)           3.4 (2.8 to 4.0)\*\*\*                          
  Fasting insulin^†^ (pmol/L)                                                                                                       
   Placebo                             68    48.7 (26.6)        45.4 (26.3)         −2.9 (−6.5 to 0.7)                              6.8 (1.6 to 11.9)\*
   Sitagliptin                         66    44.4 (24.0)        48.6 (25.6)         3.9 (0.2 to 7.5)\*                              
  HOMA‐IR^†^                                                                                                                        
   Placebo                             68    2.7 (1.6)          2.5 (1.5)           −0.1 (−0.4 to 0.1)                              0.1 (−0.2 to 0.4)
   Sitagliptin                         66    2.4 (1.5)          2.4 (1.4)           0.0 (−0.2 to 0.2)                               
  HOMA‐β^†^                                                                                                                         
   Placebo                             68    31.5 (17.8)        29.3 (19.1)         −2.2 (−5.1 to 0.7)                              9.8 (5.7 to 14.0)\*\*\*
   Sitagliptin                         66    29.8 (17.2)        37.6 (21.0)         7.6 (4.7 to 10.6)\*\*\*                         
  2‐h Post‐meal glucose^‡^ (mmol/L)                                                                                                 
   Placebo                             67    13.2 (3.7)         13.5 (3.8)          0.3 (−0.2 to 0.9)                               −2.7 (−3.6 to −1.9)\*\*\*
   Sitagliptin                         63    12.8 (3.2)         10.5 (2.9)          −2.4 (−3.0 to −1.8)\*\*\*                       
  2‐h Post‐meal insulin^‡^ (pmol/L)                                                                                                 
   Placebo                             67    302.4 (178.2)      271.5 (159.4)       −27.4 (−54.4 to −0.5)\*                         55.4 (16.6 to 94.2)\*\*
   Sitagliptin                         63    271.7 (135.0)      303.2 (170.6)       28.0 (0.2 to 55.8)\*                            
  Glucose AUC^‡^ (mmol h/L)                                                                                                         
   Placebo                             67    25.2 (5.6)         25.6 (5.5)          0.5 (−0.2 to 1.3)                               −4.2 (−5.3 to −3.0)\*\*\*
   Sitagliptin                         63    24.6 (4.4)         21.0 (4.0)          −3.6 (−4.4 to −2.8)\*\*\*                       
  Insulin AUC^‡^ (pmol h/L)                                                                                                         
   Placebo                             67    460.5 (254.2)      416.7 (212.1)       −41.7 (−69.8 to −13.6)\*\*                      84.8 (44.4 to 125.2)\*\*\*
   Sitagliptin                         63    434.5 (207.9)      479.9 (239.9)       43.1 (14.1 to 72.1)\*\*                         
  C‐peptide AUC^‡^ (nmol h/L)                                                                                                       
   Placebo                             67    3.0 (1.0)          2.8 (0.9)           −0.2 (−0.4 to −0.1)\*\*\*                       0.4 (0.2 to 0.5)\*\*\*
   Sitagliptin                         63    3.0 (0.9)          3.1 (1.0)           0.1 (0.0 to 0.3)^\*^                            
  Insulinogenic index^‡^                                                                                                            
   Placebo                             66    0.3 (0.2)          0.3 (0.2)           0.0 (−0.1 to 0.0)                               0.2 (0.1 to 0.3)\*\*\*
   Sitagliptin                         63    0.3 (0.2)          0.5 (0.4)           0.2 (0.1 to 0.2)\*\*\*                          

^†^Missing data were imputed using the last‐observation‐carried‐forward (LOCF) method. ^‡^Missing data were not imputed (i.e. LOCF method was not used). \*\*\**P *\< 0.001, \*\**P *\< 0.01, \**P *\< 0.05. AUC, total area under the concentration‐versus‐time curve; CI, confidence interval; HOMA‐β, homeostasis model assessment of β‐cell function; HOMA‐IR, homeostasis model assessment of insulin resistance; LS, least squares; SD, standard deviation.

![ Time course of HbA1c in Japanese patients with type 2 diabetes mellitus. Patients in the P/S group received placebo during the 12‐week double‐blind period and open‐label sitagliptin in the 40‐week open‐label period. Patients in the S/S group received sitagliptin (50 or 100 mg/day) for the subsequent 40 weeks. The data are shown as mean ± SE. In the double‐blind period, the method of last‐observation‐carried‐forward (LOCF) was used to impute values for HbA1c. In the open‐label period, statistics for HbA1c were calculated without LOCF, using at each time‐point the data available for that specific time‐point. The sample sizes at each time‐point are shown beneath the plots. \*\**P *\< 0.01 compared with week 0.](jdi-2-381-g2){#f2}

Both FPG and 2‐h PMG were also significantly (*P *\< 0.001) improved by sitagliptin treatment at week 12 ([Table 1](#t1){ref-type="table-wrap"}).

Results from the analysis of changes from baseline in other efficacy parameters between the treatment groups at week 12 were supportive of the primary and secondary findings, including a significant improvement in 1,5‐AG with sitagliptin treatment ([Table 1](#t1){ref-type="table-wrap"}).

### Open‐label period (weeks 12 through 52) {#ss12}

Consistent with the double‐blind period, HbA1c, FPG and 2‐h PMG showed improvements from baseline through week 52 in the S/S and P/S groups (all *P *\< 0.001, [Table 2](#t2){ref-type="table-wrap"}, Figures S1--S3). Significant changes (*P *\< 0.05) in other efficacy parameters including 1,5‐AG, HOMA‐β, post‐meal AUC of glucose, insulin, C‐peptide and the insulinogenic index were also observed in both the S/S and P/S group at week 52.

######  Results for fasting and post‐meal end‐points at week 52

                                    *n*   Week 0 mean (SD)   Week 52 mean (SD)   Change from week 0 (baseline) to week 52 (mean \[95% CI\])
  --------------------------------- ----- ------------------ ------------------- ------------------------------------------------------------
  HbA1c (%)                                                                      
   P/S                              59    7.8 (0.6)          7.2 (0.5)           −0.6 (−0.7 to −0.4)\*\*\*
   S/S                              50    8.0 (0.7)          7.3 (0.7)           −0.6 (−0.8 to −0.5)\*\*\*
  Fasting plasma glucose (mmol/L)                                                
   P/S                              59    8.0 (1.6)          7.3 (1.3)           −0.7 (−1.0 to −0.4)\*\*\*
   S/S                              50    7.8 (1.4)          7.2 (1.1)           −0.7 (−1.0 to −0.4)\*\*\*
  1,5‐anhydroglucitol (ug/mL)                                                    
   P/S                              59    7.2 (5.3)          12.0 (7.4)          4.8 (3.8 to 5.9)\*\*\*
   S/S                              50    6.5 (4.2)          11.4 (6.4)          5.0 (3.8 to 6.2) \*\*\*
  Fasting insulin (pmol/L)                                                       
   P/S                              59    47.9 (26.0)        52.3 (27.8)         4.4 (−1.0 to 9.7)
   S/S                              50    43.8 (20.3)        47.9 (21.0)         4.1 (−0.7 to 8.8)
  HOMA‐IR                                                                        
   P/S                              59    2.5 (1.5)          2.5 (1.6)           0.0 (−0.3 to 0.4)
   S/S                              50    2.3 (1.2)          2.2 (1.1)           0.0 (−0.3 to 0.2)
  HOMA‐β                                                                         
   P/S                              59    33.0 (17.9)        42.5 (26.2)         9.4 (4.6 to 14.3)\*\*\*
   S/S                              50    30.8 (17.1)        39.9 (19.4)         9.0 (4.5 to 13.5)\*\*\*
  2‐h Post‐meal glucose (mmol/L)                                                 
   P/S                              59    12.4 (3.2)         9.8 (2.3)           −2.6 (−3.4 to −1.8)\*\*\*
   S/S                              50    12.3 (3.0)         9.6 (2.3)           −2.7 (−3.4 to −2.0)\*\*\*
  2‐h Post‐meal insulin (pmol/L)                                                 
   P/S                              59    312.2 (183.6)      316.3 (190.1)       4.1 (−33.3 to 41.5)
   S/S                              50    278.9 (132.8)      307.1 (183.1)       28.2 (−11.4 to 67.9)
  Glucose AUC (mmol h/L)                                                         
   P/S                              59    23.9 (4.7)         20.1 (3.6)          −3.8 (−4.9 to −2.7)\*\*\*
   S/S                              50    23.9 (4.2)         20.3 (3.7)          −3.5 (−4.5 to −2.6)\*\*\*
  Insulin AUC (pmol h/L)                                                         
   P/S                              59    465.5 (242.7)      498.0 (245.4)       32.5 (−4.2 to 69.2)
   S/S                              50    445.5 (213.5)      490.9 (260.0)       45.4 (1.9 to 88.8)\*
  C‐peptide AUC (nmol h/L)                                                       
   P/S                              59    3.1 (1.0)          3.6 (1.0)           0.5 (0.3 to 0.7)\*\*\*
   S/S                              50    3.1 (0.9)          3.5 (0.9)           0.4 (0.2 to 0.6)\*\*\*
  Insulinogenic index                                                            
   P/S                              59    0.3 (0.2)          0.6 (0.3)           0.2 (0.1 to 0.2)\*\*\*
   S/S                              50    0.3 (0.2)          0.4 (0.3)           0.1 (0.1 to 0.2)\*\*\*

\*\*\**P *\<* *0.001, \*\**P *\<* *0.01, \**P *\<* *0.05. Missing data were not imputed. AUC, total area under the concentration‐versus‐time curve; CI, confidence interval; HOMA‐β: homeostasis model assessment of β‐cell function; HOMA‐IR: homeostasis model assessment of insulin resistance; P/S, patients received placebo in double‐blind period and sitagliptin in open‐label period; SD, standard deviation; S/S, patients received sitagliptin in double‐blind and open‐label periods.

The sitagliptin dose was uptitrated in 42 (67%) patients in the S/S group and 41 (61%) patients in the P/S group. Among those who had a HbA1c ≥7.4% at the time of uptitration (69 patients), 17 patients (25%) had a HbA1c value of \<7.4% 12 weeks after uptitration. A total of 64 (77%) patients who had their sitagliptin dose increased completed the 52 weeks of study; 30 (47%) of them had HbA1c \<7.4% at study end.

Safety {#ss13}
------

### Double‐blind period (weeks 0 through 12) {#ss14}

The incidences of clinical AE, laboratory AE, drug‐related AE and serious AE were similar in both treatment groups ([Table 3](#t3){ref-type="table-wrap"}). No laboratory AE were considered drug‐related by the investigator and none was reported as a serious AE. Two (3%) patients in the sitagliptin group (coronary artery stenosis and cerebral infarction, respectively) and none in the placebo group discontinued as a result of serious clinical AE, but neither of these AE was considered drug‐related by the investigator. Both of these patients were at increased risk for ischemic cardiovascular disease based on their medical history.

######  Safety and tolerability results

                                                  Weeks 0--12^†^ (double‐blind)   Weeks 12--52 (open‐label)               
  ----------------------------------------------- ------------------------------- --------------------------- ----------- -----------
  No. patients (*n* \[%\]) who had one or more                                                                            
   Clinical AE                                    39 (57.4)                       38 (57.6)                   54 (80.6)   52 (82.5)
   Drug‐related clinical AE^‡^                    5 (7.4)                         4 (6.1)                     3 (4.5)     6 (9.5)
   Serious clinical AE^‡^                         1 (1.5)                         3 (4.5)                     3 (4.5)     1 (1.6)
   Drug‐related serious clinical AE               0                               0                           0           0
  Number of patients (*n* \[%\]) who:                                                                                     
   Discontinued due to a clinical AE              0                               2 (3)                       0           3 (4.8)
   Died                                           0                               0                           0           0
  Number of patients (*n* \[%\]) who had:                                                                                 
   Hypoglycemia                                   2 (2.9)                         2 (3.0)                     1 (1.5)     1 (1.6)
   Nausea, vomiting or diarrhea                   1 (1.5)                         1 (1.5)                     0           2 (3.2)
  No. patients (*n* \[%\]) who had one or more:                                                                           
   Laboratory AE                                  5 (7.4)                         5 (7.6)                     16 (23.9)   17 (27.0)
   Drug‐related laboratory AE^‡^                  0                               0                           3 (4.5)     1 (1.6)
   Serious laboratory AE                          0                               0                           0           0
  No. patients (*n* \[%\]) who                                                                                            
   Discontinued due to a laboratory AE            0                               0                           0           0
  No. patients (*n* \[%\]) who had:                                                                                       
   Clinical AE^§^                                                                                                         
    Nasopharyngitis                               17 (25.0)                       11 (16.7)                   26 (38.8)   16 (25.4)
    Upper respiratory tract inflammation          3 (4.4)                         9 (13.6)                    4 (6.0)     12 (19.0)
    Periodontitis                                 0                               0                           5 (7.5)     2 (3.2)
    Weight increase                               0                               2 (3.0)                     3 (4.5)     6 (9.5)
    Osteoarthritis                                0                               1 (1.5)                     3 (4.5)     4 (6.3)
    Hypoesthesia                                  2 (2.9)                         0                           4 (6.0)     3 (4.8)
    Gastritis                                     2 (2.9)                         0                           5 (7.5)     1 (1.6)
    Joint sprain                                  1 (1.5)                         1 (1.5)                     0           4 (6.3)
   Laboratory AE^§^                                                                                                       
    Blood creatine phosphokinase increased        2 (2.9)                         1 (1.5)                     9 (13.4)    7 (11.1)
    Blood triglycerides increased                 0                               0                           5 (7.5)     0
    Alanine aminotransferase increased            1 (1.5)                         0                           1 (1.5)     4 (6.3)
    Blood lactate dehydrogenase increased         0                               0                           1 (1.5)     4 (6.3)
    Aspartate aminotransferase increased          0                               0                           0           5 (7.9)

^†^Fisher's exact test was used to test the significance of differences in weeks 0--12 between numbers of patients in the sitagliptin and placebo groups reported to have one or more clinical adverse experience (AE) overall, drug‐related clinical AE, incidence of hypoglycemia, or prespecified gastrointestinal AE (nausea, vomiting and diarrhea). All between‐group differences were non‐significant. ^‡^Considered to be possibly, probably or definitely treatment‐related by the study investigators. ^§^Specific AE for which there was a ≥5% incidence in either the sitagliptin or placebo group in the double‐blind period (from week 0 to 12), P/S or S/S group in the open‐label period (from week 12 to 52) were shown. P/S, patients received placebo in double‐blind period and sitagliptin in open‐label period; S/S, patients received sitagliptin in double‐blind and open‐label periods.

Hypoglycemia was reported at low and similar rates in both treatment groups; no patient required assistance to manage an episode of hypoglycemia, and no episode of marked severity was reported. Predefined gastrointestinal AE were also reported at low and similar incidences in both groups.

Nasopharyngitis and upper respiratory tract inflammation were the only specific AE reported, with a frequency ≥5% in either treatment group ([Table 3](#t3){ref-type="table-wrap"}), regardless of causality. Although AE of upper respiratory tract inflammation were reported more frequently in the sitagliptin group relative to the placebo group, no event was considered drug‐related by the investigator and none resulted in discontinuation.

The addition of sitagliptin or placebo to ongoing therapy with pioglitazone resulted in mean changes from baseline in bodyweight of 0.40 and −0.44 kg (both *P *\< 0.001), respectively. No meaningful changes in other safety parameters were observed in either treatment group.

### Open‐label period (weeks 12 through 52) {#ss15}

During the open‐label period, consistent with the longer period of observation in a patient population with type 2 diabetes, one or more clinical AE were reported for most patients in both the S/S and P/S groups ([Table 3](#t3){ref-type="table-wrap"}). Clinical AE reported with an incidence ≥5% in either group are shown in [Table 3](#t3){ref-type="table-wrap"}. Drug‐related clinical AE were reported in 10 and 5% of patients in the S/S and P/S groups, respectively; with the exception of constipation (two patients \[2%\]; both mild) in the S/S group, none of these events were reported to occur in more than one patient.

Serious AE were reported for one patient in the S/S group and three patients in the P/S group, all were considered not drug‐related by the investigator, and none was reported to occur in more than one patient. The incidence of hypoglycemia and gastrointestinal AE remained low and no episodes of severe hypoglycemia or events requiring assistance were reported through 52 weeks.

Laboratory AE were reported similarly in the S/S and P/S groups; none were serious, none led to discontinuation and few were reported as drug‐related ([Table 3](#t3){ref-type="table-wrap"}). The laboratory AE of increased blood creatine phosphokinase (CPK) was reported in 7 (11%) patients in the S/S group and 9 (13%) patients in the P/S group. Except for two patients in the S/S group with a slight elevation at the last study visit, all events of increased CPK were based on single elevations that resolved while the patients continued taking the study drug. No AE of increased CPK was considered drug‐related by the investigator. During the double‐blind period, laboratory AE of increased CPK were reported for 2 and 3% of patients in the sitagliptin and placebo groups, respectively. No significant mean changes from baseline in CPK levels were observed in either treatment group and there were no meaningful between‐group differences.

The incidences of clinical and laboratory AE did not change with uptitration of sitagliptin. The overall incidence of clinical AE was similar (67 patients \[81%\] and 114 patients \[86%\], respectively) between patients whose sitagliptin dose was uptitrated to 100 mg/day (*n* = 83) and the total patients (*n* = 130). The incidences of laboratory AE were similar as well (22 patients \[27%\] and 34 patients \[26%\], respectively). In no case was a patient's sitagliptin dose downtitrated from 100 to 50 mg/day.

At week 52, mean changes from baseline in bodyweight of 0.76 kg (*P *\< 0.01) and 0.82 kg (*P *\<* *0.01) were observed for the S/S group and P/S group, respectively (both *P *\< 0.01). AE of increased bodyweight were reported for nine (7% of 130) patients overall, in whom the mean weight change from baseline was 5.3 kg. Overall, there were no meaningful changes from baseline in vital signs in the long‐term safety assessment of either group.

Discussion {#ss16}
==========

In the present study, the addition of sitagliptin for 12 weeks provided a significant reduction in HbA1c relative to the placebo in Japanese patients with type 2 diabetes who had inadequate glycemic control with pioglitazone monotherapy. The proportions of patients achieving the goals of HbA1c \< 7.4 and \<6.9% with sitagliptin treatment were four and sixfold larger, respectively, than with the placebo. Significant changes were also observed in FPG, 2‐h PMG and other efficacy parameters supporting the primary efficacy results. Although changes in 1,5‐AG might not reflect changes in glycemic control as accurately as glucose itself, especially in those patients with higher HbA1c at baseline, in the present study, 1,5‐AG results were consistent with those of the other more specific glycemic parameters.

Consistent with the literature, the results of the present study show a weaker association between type 2 diabetes and increased bodyweight for Japanese patients compared with non‐Japanese patients[^16--19^](#b16 b17 b18 b19){ref-type="ref"}. In the present study, the mean baseline BMI of 26.4 kg/m^2^ was lower than that seen in previous sitagliptin studies outside of Japan (\>30 kg/m^2^)[^8,11,12,23^](#b8 b11 b12 b23){ref-type="ref"}. However, despite these differences, the improvement in glycemic parameters with sitagliptin in the present study is consistent with those from earlier studies of sitagliptin in monotherapy[^6,10^](#b6 b10){ref-type="ref"} and as an add‐on to metformin[^7,11^](#b7 b11){ref-type="ref"}, pioglitazone[^12^](#b12){ref-type="ref"} and glimepiride[^8^](#b8){ref-type="ref"} in non‐Japanese patients. This is likely to be a result of the effect of sitagliptin on insulin secretion and hepatic glucose overproduction, two defects common in both Japanese and non‐Japanese patients with type 2 diabetes.

In the current study, the efficacy of sitagliptin, as reflected by changes in HbA1c, FPG and 2‐h PMG, remained stable for up to 52 weeks. Additionally, improvements in insulin secretion were reflected by changes in HOMA‐β, insulin AUC and insulinogenic index. These findings are clinically meaningful, but should be interpreted in the context of the current study design, in which the dose regimen of sitagliptin (50 mg/day) was uptitrated to 100 mg/day if patients met predefined glycemic parameters. This therapeutic approach provided clinically meaningful glucose‐lowering effects for up to 52 weeks in Japanese patients with type 2 diabetes inadequately controlled with pioglitazone monotherapy.

The addition of sitagliptin to pioglitazone monotherapy was generally well tolerated over 12 weeks of treatment, with a safety profile similar to that of the placebo. As with efficacy, the assessment of safety data from the open‐label, uncontrolled period must be interpreted in the context of the current study design. Over 52 weeks, sitagliptin was well tolerated, with a safety profile consistent with that observed in a previous long‐term study of pioglitazone monotherapy in Japanese patients with type 2 diabetes[^24^](#b24){ref-type="ref"}. In the present study, the incidence of hypoglycemia was low and similar in both treatment groups, and remained low throughout 52 weeks, consistent with the glucose‐dependant action of incretins[^5^](#b5){ref-type="ref"}. The incidence of gastrointestinal AE was also low throughout the study period, with rates consistent with data from a previous study[^23^](#b23){ref-type="ref"}. Continuous weight gain is a well‐known, dose‐related effect of treatment with PPARγ agonists[^14,25--29^](#b14 b25 b26 b27 b28 b29){ref-type="ref"}. In previous studies, it has generally been observed that treatment with sitagliptin is neutral with respect to bodyweight[^30^](#b30){ref-type="ref"}. In the double‐blind period of the present study, a slight increase in bodyweight, that was statistically significant, was observed with sitagliptin treatment, compared with a small decrease with the placebo. This finding is not unexpected, as it is well known that poor glycemic control is associated with weight loss, as was observed in the placebo group, and the significant improvement in glycemic parameters observed with sitagliptin treatment might explain the small increase in bodyweight. Over the full 1 year of the study, both groups gained approximately 0.8 kg, which is consistent with the weight gain observed in other studies with pioglitazone[^14^](#b14){ref-type="ref"}.

In conclusion, after 12 weeks of treatment, the addition of sitagliptin 50 mg/day to Japanese patients with type 2 diabetes inadequately controlled by diet and exercise and ongoing pioglitazone therapy resulted in significant reductions from baseline in HbA1c and other efficacy parameters relative to the placebo. Furthermore, the improvements in HbA1c and other glycemic parameters observed early in the double‐blind treatment period of the present study appeared to remain stable throughout the 52 weeks. In addition, the findings in the present study suggest that sitagliptin uptitration to 100 mg provides further opportunity for patients to meet glycemic goals. The addition of sitagliptin to pioglitazone was generally well tolerated, with a low incidence of hypoglycemia and gastrointestinal AE, and a small increase in bodyweight.
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